Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28714
Title: Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.
Austin Authors: Walia, N;Eratne, Dhamidhu;Loi, S M;Li, Q-X;Varghese, S;Malpas, C B;Walterfang, Mark;Evans, A H;Parker, S;Collins, S J;Masters, C L;Velakoulis, D
Affiliation: The Florey Institute of Neuroscience and Mental Health
National Dementia and Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC, Australia
Melbourne Neuropsychiatry Centre & Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
Department of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia
Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia
Clinical Outcomes Research Unit (CORe), Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia
Issue Date: 15-Jan-2022
Date: 2021
Publication information: Journal of the Neurological Sciences 2022; 432: 120088
Abstract: Determining disease severity and predicting prognosis in younger onset-dementia (YOD) remains challenging. Whether CSF biomarkers neurofilament light (NfL), tau and amyloidβ 42 (Aβ42) can help provide such information has been underexplored. Patients with YOD and CSF analysis were identified. We compared baseline NfL, tau and Aβ42 concentrations with contemporaneous Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) scores to assess their association with severity of cognitive impairment. Cognitive decline, as measured by longitudinal NUCOG assessment, was correlated against baseline biomarker levels to assess their utility in predicting the rate of cognitive decline. 78 patients with YOD (mean age = 56 years, SD = 8) and CSF analysis were identified. Dementia types included Alzheimer's disease, behavioural variant frontotemporal dementia, dementia not-otherwise-specified and other. Tau was associated with contemporaneous memory dysfunction (r = -0.556, 95% CI:[-0.702,-0.393], p < .001). 21 patients had longitudinal cognitive assessment up to 82 months from CSF sampling. NfL was associated with the rate of executive function decline (r = 0.755, 95% CI:[0.259,0.937], p < .001). Aβ42 was associated with the rate of memory decline (r = -0.582, 95% CI:[-0.855,-0.274], p = .007) and rate of total NUCOG decline (r = -0.515, 95% CI: [-0.809, -0.227], p = .017). CSF tau is related to contemporaneous memory impairment in YOD. NfL and Aβ42 levels are associated with the rate of executive function and memory decline, respectively, and may have a role in prognostication in YOD.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28714
DOI: 10.1016/j.jns.2021.120088
ORCID: 0000-0002-1389-3691
0000-0002-3226-7645
0000-0001-8438-3763
0000-0002-5245-6611
0000-0003-3072-7940
Journal: Journal of the Neurological Sciences
PubMed URL: 34922179
Type: Journal Article
Subjects: CSF biomarkers
Cognitive decline
Neurofilament light
Tau
Younger-onset dementia
amyloidβ 42
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.